- Home
- ADVM vs XCUR Comparison
ADVM vs XCUR Comparison
Compare ADVM & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADVM
- XCUR
- Stock Information
- Founded
- ADVM 2006
- XCUR 2011
- Country
- ADVM United States
- XCUR United States
- Employees
- ADVM N/A
- XCUR N/A
- Industry
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- XCUR Biotechnology: Pharmaceutical Preparations
- Sector
- ADVM Health Care
- XCUR Health Care
- Exchange
- ADVM Nasdaq
- XCUR Nasdaq
- Market Cap
- ADVM 59.5M
- XCUR 67.8M
- IPO Year
- ADVM 2014
- XCUR N/A
- Fundamental
- Price
- ADVM $2.22
- XCUR $9.87
- Analyst Decision
- ADVM Strong Buy
- XCUR
- Analyst Count
- ADVM 5
- XCUR 0
- Target Price
- ADVM $26.40
- XCUR N/A
- AVG Volume (30 Days)
- ADVM 430.7K
- XCUR 11.5K
- Earning Date
- ADVM 05-14-2025
- XCUR 06-16-2025
- Dividend Yield
- ADVM N/A
- XCUR N/A
- EPS Growth
- ADVM N/A
- XCUR N/A
- EPS
- ADVM N/A
- XCUR N/A
- Revenue
- ADVM $1,000,000.00
- XCUR $500,000.00
- Revenue This Year
- ADVM N/A
- XCUR N/A
- Revenue Next Year
- ADVM $42.58
- XCUR N/A
- P/E Ratio
- ADVM N/A
- XCUR N/A
- Revenue Growth
- ADVM N/A
- XCUR N/A
- 52 Week Low
- ADVM $1.78
- XCUR $1.44
- 52 Week High
- ADVM $10.14
- XCUR $36.00
- Technical
- Relative Strength Index (RSI)
- ADVM 36.90
- XCUR 42.75
- Support Level
- ADVM $2.10
- XCUR $9.01
- Resistance Level
- ADVM $2.33
- XCUR $11.00
- Average True Range (ATR)
- ADVM 0.24
- XCUR 0.42
- MACD
- ADVM 0.03
- XCUR -0.05
- Stochastic Oscillator
- ADVM 32.65
- XCUR 30.18
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
About XCUR Exicure Inc.
Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.